ロード中...

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma

BACKGROUND: Researches on programmed cell death (PD-1) as neoadjuvant immunotherapy for resectable non-small cell lung cancer is underway, which brings hope for individuals with the disease. However, a study dedicated to lung squamous cell carcinoma (LUSC) specifically has yet to be conducted. Now,...

詳細記述

保存先:
書誌詳細
出版年:J Thorac Dis
主要な著者: Shen, Dijian, Wang, Jiangfeng, Wu, Jie, Chen, Sheng, Li, Jianqiang, Liu, Jinshi, Chen, Qixun, Jiang, Youhua
フォーマット: Artigo
言語:Inglês
出版事項: AME Publishing Company 2021
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8024839/
https://ncbi.nlm.nih.gov/pubmed/33841966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-21-103
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!